These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 33010818)

  • 1. Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice.
    Sun R; Luo H; Su J; Di S; Zhou M; Shi B; Sun Y; Du G; Zhang H; Jiang H; Li Z
    Mol Ther; 2021 Jan; 29(1):60-74. PubMed ID: 33010818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3/NF-κB/SDF-1α axis to enhance efficacy against pancreatic cancer.
    Sun R; Sun Y; Wu C; Liu Y; Zhou M; Dong Y; Du G; Luo H; Shi B; Jiang H; Li Z
    Mol Ther; 2023 Nov; 31(11):3193-3209. PubMed ID: 37735875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
    Ghonim MA; Ibba SV; Tarhuni AF; Errami Y; Luu HH; Dean MJ; El-Bahrawy AH; Wyczechowska D; Benslimane IA; Del Valle L; Al-Khami AA; Ochoa AC; Boulares AH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer.
    Liu Y; Sun Y; Wang P; Li S; Dong Y; Zhou M; Shi B; Jiang H; Sun R; Li Z
    J Transl Med; 2023 Apr; 21(1):255. PubMed ID: 37046312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
    Nalawade SA; Shafer P; Bajgain P; McKenna MK; Ali A; Kelly L; Joubert J; Gottschalk S; Watanabe N; Leen A; Parihar R; Vera Valdes JF; Hoyos V
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
    Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
    J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.
    Long AH; Highfill SL; Cui Y; Smith JP; Walker AJ; Ramakrishna S; El-Etriby R; Galli S; Tsokos MG; Orentas RJ; Mackall CL
    Cancer Immunol Res; 2016 Oct; 4(10):869-880. PubMed ID: 27549124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
    Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
    Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor.
    Gao G; Liao W; Shu P; Ma Q; He X; Zhang B; Qin D; Wang Y
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37591632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models.
    Lee HH; Kim I; Kim UK; Choi SS; Kim TY; Lee D; Lee Y; Lee J; Jo J; Lee YT; Lee HJ; Kim SJ; Ahn JS
    Neoplasia; 2022 Feb; 24(2):98-108. PubMed ID: 34954452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
    Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
    J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated hepatic stellate cells regulate MDSC migration through the SDF-1/CXCR4 axis in an orthotopic mouse model of hepatocellular carcinoma.
    Xu Y; Fang F; Jiao H; Zheng X; Huang L; Yi X; Zhao W
    Cancer Immunol Immunother; 2019 Dec; 68(12):1959-1969. PubMed ID: 31641797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
    Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
    Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
    Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
    [No Abstract]   [Full Text] [Related]  

  • 18. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
    Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
    J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
    Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
    Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
    Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.